Literature DB >> 29216040

Targeted cellular immunotherapy for T cell malignancies.

Teresa Palomero1,2, Adolfo Ferrando1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29216040      PMCID： PMC5848213          DOI： 10.1038/nm.4458

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  6 in total

Review 1.  T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex.

Authors:  R H Schwartz
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

2.  Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Authors:  Carlos A Ramos; Barbara Savoldo; Vicky Torrano; Brandon Ballard; Huimin Zhang; Olga Dakhova; Enli Liu; George Carrum; Rammurti T Kamble; Adrian P Gee; Zhuyong Mei; Meng-Fen Wu; Hao Liu; Bambi Grilley; Cliona M Rooney; Malcolm K Brenner; Helen E Heslop; Gianpietro Dotti
Journal:  J Clin Invest       Date:  2016-06-06       Impact factor: 14.808

3.  Organization and sequences of the diversity, joining, and constant region genes of the human T-cell receptor beta chain.

Authors:  B Toyonaga; Y Yoshikai; V Vadasz; B Chin; T W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

4.  The role of novel immunotherapies in non-Hodgkin lymphoma.

Authors:  Allyson Pishko; Sunita D Nasta
Journal:  Transl Cancer Res       Date:  2017-02       Impact factor: 1.241

Review 5.  T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway.

Authors:  Kathrin Warner; Nicole Weit; Giuliano Crispatzu; Joan Admirand; Dan Jones; Marco Herling
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

Review 6.  The many important facets of T-cell repertoire diversity.

Authors:  Janko Nikolich-Zugich; Mark K Slifka; Ilhem Messaoudi
Journal:  Nat Rev Immunol       Date:  2004-02       Impact factor: 53.106
  6 in total
  4 in total

Review 1.  Can one target T-cell ALL?

Authors:  Adolfo Ferrando
Journal:  Best Pract Res Clin Haematol       Date:  2018-10-17       Impact factor: 3.020

Review 2.  The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.

Authors:  Marta Weronika Lato; Anna Przysucha; Sylwia Grosman; Joanna Zawitkowska; Monika Lejman
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 3.  Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.

Authors:  Muhammad Sadeqi Nezhad; Meghdad Abdollahpour-Alitappeh; Behzad Rezaei; Mahboubeh Yazdanifar; Alexander Marcus Seifalian
Journal:  Pharm Res       Date:  2021-06-10       Impact factor: 4.200

4.  One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence.

Authors:  Yingjie Qing; Hui Li; Yunzi Zhao; Po Hu; Xiangyuan Wang; Xiaoxuan Yu; Mengyuan Zhu; Hongzheng Wang; Zhanyu Wang; Qinglong Guo; Hui Hui
Journal:  Oxid Med Cell Longev       Date:  2021-09-21       Impact factor: 6.543
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.